"20/20 Gene Systems" CEO Jonathan Cohen Discusses His "Jobs Act" Crowdfunding Offering on the "Reg.A Money Show"
"20/20 Gene Systems" is proving why crowdfunding portals are so important for an offering’s success. The company is seeking investors as they plan to introduce "OneTEST," a proprietary algorithm designed to provide a more accurate cancer risk profile for early cancer detection.
Las Vegas, NV, November 17, 2017 --(PR.com)-- The Reg.A Funding Group announced today that they have published their latest “Reg.A+ Money Show” radio podcast which features “20/20 Gene Systems” CEO Jonathan Cohen as he explains exactly what his company does, its goals, strategies, and how investors can get involved in their efforts on the Microventures Crowdfunding portal.
Cancer is the second leading cause of death in the world. However, as Mr. Cohen mentions on the podcast, many tumors are not lethal if detected early enough to be surgically removed before they spread. 20/20 GeneSystems’ mission is to reduce cancer deaths in the U.S. and around the world through early detection and precision medicine.
Besides being syndicated on the iHeartRadio Network, you can access the radio show podcast here: http://ipotogo.com/2020
Said “Reg.A Money Show” co-host Ron Costa, "We were happy to have Mr. Cohen on the show to discuss his company's vision. Cancer touches so many families, it's good to see there are crowdfunding investment opportunities out there specifically dedicated to help battle this dreaded disease.”
About 20/20 GeneSystems:
20/20 GeneSystems, Inc. is a Rockville, MD-based company focused on reducing cancer mortality worldwide. They have pioneered a novel approach called “20/20 Hindsight” of continuous machine learning using large patient data sets of biomarker values with clinical factors such as age, gender, and smoking history to improve the accuracy of the most widely used cancer biomarkers. Their flagship product, “OneTEST” – a new multi cancer test which can help detect over 6 types of cancer, with up to 90% accuracy, using a standard blood test – will be available in the US beginning Q2 2018.
About The Reg.A Money Show
The “Reg.A Money Show” provides information and Reg.A education from the founders over at the “Reg.A Funding Group” as well as market insights from a variety of industry experts who appear on the show as guests. The show is hosted by Ron Costa and Miguel Dotres, who bring a wealth of information in regards to Reg A+, SEC filings, social media marketing, and various other topics in an entertaining and informative format. The podcast is quickly emerging as a “must listen” to all those interested in issuing Reg.A paper or investors interested in participating in a company’s Regulation A+ offering.
About The Reg.A Funding Group
With years of experience in the capital markets and proven results with social marketing, the Reg.A Funding Group provides real world, effective Regulation A advisory services for startup, growth and acquisition financing, while specializing in helping companies raise money with Regulation A+ Tier 1 and Tier 2 crowdfunding offerings. The Reg. A Funding Group can be reached at 612-888-REGA or at info@regamoney.com
Cancer is the second leading cause of death in the world. However, as Mr. Cohen mentions on the podcast, many tumors are not lethal if detected early enough to be surgically removed before they spread. 20/20 GeneSystems’ mission is to reduce cancer deaths in the U.S. and around the world through early detection and precision medicine.
Besides being syndicated on the iHeartRadio Network, you can access the radio show podcast here: http://ipotogo.com/2020
Said “Reg.A Money Show” co-host Ron Costa, "We were happy to have Mr. Cohen on the show to discuss his company's vision. Cancer touches so many families, it's good to see there are crowdfunding investment opportunities out there specifically dedicated to help battle this dreaded disease.”
About 20/20 GeneSystems:
20/20 GeneSystems, Inc. is a Rockville, MD-based company focused on reducing cancer mortality worldwide. They have pioneered a novel approach called “20/20 Hindsight” of continuous machine learning using large patient data sets of biomarker values with clinical factors such as age, gender, and smoking history to improve the accuracy of the most widely used cancer biomarkers. Their flagship product, “OneTEST” – a new multi cancer test which can help detect over 6 types of cancer, with up to 90% accuracy, using a standard blood test – will be available in the US beginning Q2 2018.
About The Reg.A Money Show
The “Reg.A Money Show” provides information and Reg.A education from the founders over at the “Reg.A Funding Group” as well as market insights from a variety of industry experts who appear on the show as guests. The show is hosted by Ron Costa and Miguel Dotres, who bring a wealth of information in regards to Reg A+, SEC filings, social media marketing, and various other topics in an entertaining and informative format. The podcast is quickly emerging as a “must listen” to all those interested in issuing Reg.A paper or investors interested in participating in a company’s Regulation A+ offering.
About The Reg.A Funding Group
With years of experience in the capital markets and proven results with social marketing, the Reg.A Funding Group provides real world, effective Regulation A advisory services for startup, growth and acquisition financing, while specializing in helping companies raise money with Regulation A+ Tier 1 and Tier 2 crowdfunding offerings. The Reg. A Funding Group can be reached at 612-888-REGA or at info@regamoney.com
Contact
Reg.A Funding Group
Ron Costa
612-888-REGA
www.regamoney.com
Ron Costa
612-888-REGA
www.regamoney.com
Contact
Categories